Light Activated Immunomodulation and in situ Scaffolding to Enhance MSC Therapy
About This Grant
PROJECT SUMMARY Human mesenchymal stem cells (hMSCs) can be isolated from various adult tissues including bone marrow, fat tissues, dental pulp and synovium, and exhibit therapeutic promise for tissue repair, regeneration, and treatment of chronic immune and degenerative diseases due to their multipotent differentiation ability, trophic factor secretion, and immunomodulatory functions. However, their clinical efficacy remains limited by two barriers: (i) immune-mediated clearance of transplanted cells and (ii) poor retention and engraftment within injured tissues. Even autologous or well-matched allogeneic hMSCs are frequently recognized as “non-self” after their transplantation, leading to rapid cell loss before therapeutic benefits are realized. Overcoming immune rejection and microenvironmental insufficiency is therefore critical to advance hMSC-based therapies. Systemic immunomodulators can partially mitigate host rejection but often cause off-target effects, while conventional scaffolding like hydrogels provides structural support yet rarely influences immune responses. To address these limitations, we propose a light-activated hydrogel platform that integrates local immunomodulation with in situ scaffolding under a single, spatiotemporally defined stimulus. To achieve this objective, we will pursue two aims: 1) design, synthesis and characterization of BEPA-photocaged hydrogel complex for controlled immunomodulator and hydrogel formation, and 2) preclinical evaluation of BEPA- photocaged hydrogel complex for immune-permissive and ECM-mimetic stem cell engraftment. The proposed platform is expected to establish a “regenerative niche” that is both immune-compatible and mechanically supportive, thereby improving hMSC survival, retention, and integration. The approach is innovative in three ways: (i) a light-activated photocage enabling precise, on-demand immunomodulation, (ii) an injectable, light- triggering hydrogelator that surpasses conventional scaffolds, and (iii) a unified near-infrared (NIR) control axis that simultaneously regulates immune modulation and scaffold formation. By converting engraftment into a programmable event, this strategy provides effectively spatiotemporal control over stem cell transplantation. The anticipated outcome is a safer and more effective platform for regenerative medicine with broad translational potential.
Grant Summary
Light Activated Immunomodulation and in situ Scaffolding to Enhance MSC Therapy is a NIGMS - National Institute of General Medical Sciences grant providing up to $143K for university, nonprofit, healthcare org. Applications are due 2030-05-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $143K
2030-05-31
- 1Confirm your organization is eligible for Light Activated Immunomodulation and in situ Scaffolding to Enhance MSC Therapy from NIGMS - National Institute of General Medical Sciences, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIGMS - National Institute of General Medical Sciences before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIGMS - National Institute of General Medical Sciences's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Light Activated Immunomodulation and in situ Scaffolding to Enhance MSC Therapy: Frequently Asked Questions
Who is eligible for the Light Activated Immunomodulation and in situ Scaffolding to Enhance MSC Therapy?
Light Activated Immunomodulation and in situ Scaffolding to Enhance MSC Therapy is offered by NIGMS - National Institute of General Medical Sciences and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Light Activated Immunomodulation and in situ Scaffolding to Enhance MSC Therapy provide?
Light Activated Immunomodulation and in situ Scaffolding to Enhance MSC Therapy provides up to $143K per award from NIGMS - National Institute of General Medical Sciences. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Light Activated Immunomodulation and in situ Scaffolding to Enhance MSC Therapy deadline?
Applications for Light Activated Immunomodulation and in situ Scaffolding to Enhance MSC Therapy are due 2030-05-31 (open). Because deadlines can change, verify the date with the funder, NIGMS - National Institute of General Medical Sciences, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Light Activated Immunomodulation and in situ Scaffolding to Enhance MSC Therapy?
To apply for Light Activated Immunomodulation and in situ Scaffolding to Enhance MSC Therapy, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIGMS - National Institute of General Medical Sciences.